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Abstract
Background
Atrial fibrillation (AF) is predicted to affect around 17.9 million individuals in Europe by 2060.
The disease is associated with severe electrical and structural remodelling of the heart, and
increased the risk of stroke and heart failure. In order to improve treatment and find new
drug targets, the field needs to better comprehend the exact molecular mechanisms in
these remodelling processes.
Objectives
This study aims to identify gene and miRNA networks involved in the remodelling of AF
hearts in AF patients with mitral valve regurgitation (MVR).
Methods
Total RNA was extracted from right atrial biopsies from patients undergoing surgery for
mitral valve replacement or repair with AF and without history of AF to test for differentially
expressed genes and miRNAs using RNA-sequencing and miRNA microarray. In silico pre-
dictions were used to construct a mRNA-miRNA network including differentially expressed
mRNAs and miRNAs. Gene and chromosome enrichment analysis were used to identify
molecular pathways and high-density AF loci.
Results
We found 644 genes and 43 miRNAs differentially expressed in AF patients compared to
controls. From these lists, we identified 905 pairs of putative miRNA-mRNA interactions,
including 37 miRNAs and 295 genes. Of particular note, AF-associated miR-130b-3p, miR-
338-5p and miR-208a-3p were differentially expressed in our AF tissue samples. These
miRNAs are predicted regulators of several differentially expressed genes associated with
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cardiac conduction and fibrosis. We identified two high-density AF loci in chromosomes
14q11.2 and 6p21.3.
Conclusions
AF in MVR patients is associated with down-regulation of ion channel genes and up-regula-
tion of extracellular matrix genes. Other AF related genes are dysregulated and several are
predicted to be targeted by miRNAs. Our novel miRNA-mRNA regulatory network provides
new insights into the mechanisms of AF.
Introduction
Atrial Fibrillation (AF) is the most common type of cardiac arrhythmia. The disease represents
a major economic burden and prevalence is predicted to increase over the next decades both
in Europe and the United States [1]. Genetic variants are well documented in cases of early-
onset and ‘lone’ AF [2,3]. Additionally, more than one hundred susceptibility loci were identi-
fied by population-based, genome-wide association studies (GWAS) [4,5].
The vast majority of AF patients are over 75 years old indicating that AF is an age-related
disease. The disease often starts by short self-terminating episodes originating from a trigger in
a vulnerable substrate that leads to rapid focal ectopic firing and re-entry of electrical signals in
the atria. In some cases, AF can gradually develop to a permanent condition through a process
called remodelling [6]. Electrical remodelling results from ion channel dysregulation while
structural remodelling is characterized by increased fibrosis, atrial dilation and conduction
abnormalities [7,8]. The available therapeutic options in clinical practice have limited effi-
ciency, especially in those patients with more progressed AF, likely due to higher severity of tis-
sue remodelling [9].
Valvular heart disease (VHD) is an established risk factor for AF [10]. However, not all
patients with valve disorders develop AF, suggesting that some VHD patients are more predis-
posed to develop AF. Differences in the remodelling of affected hearts might be a secondary
factor predisposing to AF in these patients.
MicroRNAs (miRNAs) are a class of highly conserved short non-protein-coding RNAs.
These 18–24 nucleotides RNA molecules are known to negatively regulate the expression of
complementary target genes by binding to the 3’-untranslated region (UTR) of messenger
RNAs (mRNAs) in the cytosol, promoting either mRNA degradation or inhibiting translation
[11]. MiRNAs can be classified as intergenic, intronic and exonic, and the expression of intro-
nic and exonic miRNAs is mainly controlled by the promoter of the host gene [12].
Original reports on the role of miR-1 in cardiogenesis have triggered a large body of
research dealing with the role of miRNAs in cardiac development and pathological processes
[13]. Following this report, abnormal expression of many other miRNAs has been described in
various types of cardiac disorders [14]. In the context of AF, different studies have shown a
role of miRNAs in the deregulation of ion channels based on gene expression analyses of tissue
samples from AF patients and additional functional studies [15–17]. Cardiac fibrosis was also
shown to be influenced by a number of miRNAs, such as miR-133a [18,19]. However, much is
yet to be learned about the complete role of miRNAs in arrhythmogenesis. Hence, the analysis
of miRNAs expression can give important insight into regulatory mechanisms involved in dis-
ease, especially when combined with gene expression profiling studies [20,21].
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The present study identifies several miRNAs and genes that may contribute to the develop-
ment of AF-associated with VHD and illustrates a miRNA-mRNA network with hundreds of
putative regulatory interactions from studying tissue samples from AF patients and controls
with mitral valve regurgitation (MVR).
Materials and methods
Patients and tissue samples
Right atrial (RA) posterior wall tissue biopsies were obtained from unrelated Caucasian
patients undergoing open-heart surgery for mitral valve replacement or repair at the Univer-
sity Hospital of Copenhagen (Rigshospitalet), as previously described [22]. From these, six
patients with AF sustained for at least two months were selected. The control group included
six patients in sinus rhythm (SR) and with no previous history of AF who were selected
according to age and gender match. Cardiac disease, hypertension and type 2 diabetes mellitus
were used as exclusion criteria.
The study was approved by the Ethics Committee of the Capital Region of Copenhagen
(protocol reference no. 16238), in accordance with the Declaration of Helsinki. Written
informed consent for the use of clinical information and biological samples was provided by
all participants. Clinical data from all subjects was obtained through questionnaires and clini-
cal records from the Danish health care system.
RNA preparation
Total RNA including small RNAs was extracted from RA biopsies of six AF patients and six
control patients using the miRNeasy kit (QIAGEN, Hilden, Germany) according to manufac-
turer’s instructions. RNA concentration was measured in a NanoDrop 2000 (ThermoScienti-
fic, Wilmington, USA) and quality was assessed in a 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA). RNA samples with a RIN> 6 were used in further experiments. For
details see Supplementary methods in S1 File.
RNA-sequencing
Libraries were prepared from ribosomal RNA depleted RNA samples using the TruSeq
Stranded Total RNA Library Prep Kit (Illumina, San Diego, California, USA). Libraries were
sequenced on an Illumina HiSeq 2500. The control sample HS24 was not used due to low
amount of input RNA. The raw sequencing data is available in the Electronic Research Data
Archive (University of Copenhagen), see Data Availability section.
Transcriptome sequencing analysis
Raw paired-end reads were aligned to the human GRCh38 reference transcriptome using the
Kallisto pseudoaligner with default options [23]. Kallisto quantifies the abundance of reads on
transcript level. The resulting quantification files were imported to R for downstream analysis.
Transcript counts were collapsed to gene level. Differentially expressed genes (DEGs) in AF
compared to controls were obtained using the Bioconductor package DEseq2 [24]. Genes with
false discovery rate< 0.05 and log2fold-change (FC) above 1 or below -1 were considered
DEGs. Principal component analysis (PCA) and unsupervised hierarchical clustering of sam-
ple-to-sample distance matrixes were used to analyse sample clustering according to transcrip-
tomic similarities.
DEGs were compared with genes of interest including 1) AF-associated genes from geno-
mic, transcriptomic and proteomic studies from a broad literature search and 2) genes
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involved in mechanisms of interest, such as fibrosis, cardiac contraction and ion channel cur-
rents, from GO terms and HUGO Gene Nomenclature Committee.
MiRNAs microarray
Microarrays were performed with the exact same RNA samples used for the RNA-seq experi-
ments. Mature miRNA transcripts were hybridized to the GeneChipS1 miRNA 4.0 Array
(Affymetrix, Santa Clara, USA). Raw CEL data files are available at the Electronic Research
Data Archive (University of Copenhagen), see Data Availability section.
Data generated by the Affymetrix’s miRNA array was normalized using the robust multi-
array average method [25]. Quality metrics showed one control sample (HS24) as an outlier
(S1 Fig in S1 File). FC values and p-values (p) of expression changes were calculated using the
Limma package in R/Bioconductor project [26]. A cut-off p< 0.01 was used for selection of
differentially expressed miRNAs. No FC cut-off was applied. Samples and differentially
expressed miRNAs were subjected to unsupervised hierarchical clustering and plotted as a
heat map.
Validation of RNA-seq and microarray by quantitative PCR
Qualitative polymerase chain reaction (qPCR) was performed to confirm the reliability of
RNA-seq and microarray data. cDNA was synthesized using the Precision nanoScript2
Reverse Transcription kit (PrimerDesign, Southampton, United Kingdom) for mRNAs and
the Universal cDNA Synthesis kit II (Exiqon, Wobrun, Massachusetts, USA) for miRNAs. The
expression of selected genes was measured using Taqman double dye probes and Precision-
PLUS MasterMix with ROX (PrimerDesign, Southampton, United Kingdom). The miRNAs
qPCR reactions were performed using commercial miRCURY LNA™ Universal RT microRNA
PCR primers and the ExiLENT SYBR1 Green master mix (Exiqon, Wobrun, Massachusetts,
USA). All experiments were performed in a light cycler CFX Connect Real-Time System
(BIO-RAD, Hertfordshire, UK). The following genes–KCNA4, ACTN2, KCNK3, NANOG,
TNNT2, KCNQ5, KCNJ5 and KCNB1, and miRNAs—miR-143-5p, miR-192-5p, miR-187-3p,
miR-208b-3p, miR-338-5p, miR-335-5p, miR-432-5p, miR-490-5p, miR-499a-5p, miR-503-5p
and miR-92b-3p, were investigated. YWHAZ and RPL13A were used as references to normal-
ize the results, while miRNA-16-5p and miR-103a-3p were used to normalize the miRNAs
results. Relative expression and FC values were calculated using the 2-ΔΔCt method.
Statistical analysis
Statistical analysis was performed on GraphPad Prism 7 (GraphPad Software Inc., San Diego,
USA). Mann-Whitney U-test and was applied for comparison of continuous variables. Patient
data is presented as mean ± standard deviation (SD) and percentage. P< 0.05 was considered
statistically significant.
miRNA target genes prediction
Candidate target genes of the differentially expressed miRNAs were obtained using the miR-
Walk3 target prediction database [27,28]. The programme output includes predictions from
miRWalk’s machine learning approach (TarPmiR) and experimentally validated interaction
from miRTarBase. The 3’-UTR of genes was selected as putative binding site and only predic-
tions with a binding probability above 0.95 were accepted. Afterwards, miRNA-gene interac-
tions in which the target gene was included in our DEGs list were kept and all the others were
filtered out. Normalized expression levels from microarray and RNA-seq were used to evaluate
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the correlation between each miRNA-gene pair using Spearman’s correlation coefficient in
order to find monotonic relations, rather than just linear, given the different magnitudes used
for the RNA-seq and microarray experiments. Subsequently, interaction with a negative corre-
lation below -0.5 were used to construct a miRNA-gene regulatory network in Cytoscape ver-
sion 3.6.1 [29]. Filtering criteria was applied to the networks in order to help visualize and
identify relevant interactions. Secondary miRNA-gene networks were built for up- and down-
regulated miRNAs previously association with AF in expression studies [30–32] and respective
predicted target genes.
Functional enrichment analysis
To better understand the functional role of differentially expressed miRNAs and target genes,
a functional enrichment analysis of the targeted genes after filtering was performed using the
Database for Annotation, Visualization and Integrated Discovery (DAVID) [33]. The same
analysis was performed with the full list of DEGs from RNA-seq experiments. Our enrichment
analysis was focused on gene ontology (GO) terms and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways using an enrichment cut-off of p< 0.05 after Benjamini-Hoch-
berg correction.
Positional enrichment of genetic elements
Up- and down-regulated genes and miRNAs were plotted together with AF-associated single
nucleotide polymorphisms (SNPs), according to chromosome position, to visualize possible
clusters of these genetic elements. AF SNPs were retrieved from published data and the
Human Short Variants dataset from Ensembl Variation 96 [34]. The location of the published
SNPs had to be converted from Hg19 assembly to Hg38 using the UCSC liftOver tool. For the
rest of the elements, genomic location and cytogenetic band information was retrieved from
Biomart (Bioconductor). The nearest gene(s) to each SNP genome coordinate were obtained
to plot together with the matching SNP. For 81 SNPs retrieved, no associated gene was found.
A cluster was defined as two or more consecutive elements overlapping or not further than 20
kbp. Clusters including five or more co-localized elements of any type were considered as
high-density regions. Subsequently, high-density regions comprising exclusively SNPs were
excluded from our analysis. The total number of elements per chromosome was normalized to
chromosome size and/or gene density. Lastly, the genomic location of DE miRNAs and genes
was used to assess co-expression patterns between intronic or exonic miRNAs and host genes.
Results
Patient characteristics
RA posterior wall biopsies were obtained from MVR patients with (n = 6) and without (n = 6)
AF undergoing surgery for valve replacement or repair. Clinical characteristics of all subjects
are listed in Table 1. There were no significant differences between the groups apart from AF
history. Left atrial (LA) size was increased in both groups. Ejection fraction (EF) was lower in
AF subjects but the difference was not significant. EF values were unavailable in one subject
from each group, while one LA size measurement was unavailable in the AF group.
Gene expression signature of AF tissues
We investigated differences in gene expression between AF and control patients using RNA-
sequencing. PCA showed that males and females in the AF group were separated by PC1 (Fig
1A). No other characteristics reported in Table 1 contribute to the clustering of samples. S2 Fig
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in S1 File represents clustering of samples according to sample-to-sample matrix distances.
From the 44,852 genes detected in our samples, 644 were differentially expressed in the AF atrial
samples with an adj.p< 0.05 and log2FC>1 or< -1 (Fig 1B). Of these, 265 genes were up-regu-
lated and 379 were down-regulated. A complete list of DEGs is provided in D1 in S1 Dataset.
Pathway and gene ontology enrichment analysis was performed separately in up- and
down-regulated genes (Fig 1C and 1D). We found that down-regulated genes were enriched
for “integral component of plasma membrane”, “regulation of ion transmembrane transport”
and “extracellular region”, while up-regulated genes were greatly involved in “extracellular
space”, “nucleosome” and “mitotic nuclear division”. A full list of GO terms and KEGG path-
ways enriched in up- and down-regulated genes is available in D2 in S1 Dataset. We validated
the RNA-seq results by testing the expression of eight genes in five AF and five control samples
using qPCR quantification (S3 Fig in S1 File). The correlation between qPCR and RNA-seq
results was high for all the genes tested.
We analysed the dataset to prioritize genes that may be involved in electrical remodelling,
structural remodelling or genetic variants associated with AF in GWAS and familial studies.
Comparative analysis of DEGs with AF-associated genes and genes involved in mechanisms of
interest resulted in 57 up-regulated and 94 down-regulated genes, marked in D1 in S1 Dataset.
Table 1. Clinical characteristics of the study population.
AF patients (N = 6) Controls (N = 6)
Gender 3 males (50) 3 males (50)
Age (years) 59.3 ± 9.2 59.3 ± 8.7
BMI (kg/m2) 24.6 ± 1.6 22.5 ± 3.3
AF Type: Paroxysmal 0 (0) NA
2 (33.3) NA
4 (66.7) NA
AF duration (months) 2–14 NA
Smoking 3 (50) 2 (33.3)
Alcohol consumption (units/week)
�7 4 (66.7) 2 (33.3)
8–14 1 (16.7) 2 (33.3)
15–21 1 (16.7) 2 (33.3)
>21 0 (0) 0 (0)
Hypertension 0 (0) 0 (0)
Type II diabetes mellitus 0 (0) 0 (0)
Heart failure symptoms (NYHA):
I 1 (16.7) 1 (16.7)
II 3 (50) 4 (66.7)
III 2 (33.3) 1 (16.7)
IV 0 (0) 0 (0)
Left atrial dilation1,2 [35]:
Normal 0 (0) 0 (0)
Moderate 1 (16.7) 1 (16.7)
Severe 4 (66.7) 5 (83.3)
Ejection Fraction1 56 ± 6.5 67 ± 9.7
1 One or two unavailable values
2 Determined using biplane Simpson model; AF = atrial fibrillation; BMI = body mass index; NA–not applicable;
NYHA = New York Heart Association classification; Values are shown as n (%) or mean ± SD.
https://doi.org/10.1371/journal.pone.0232719.t001
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Specifically, the analysis showed nine genes affected by AF-associated genetic variants, 14
down-regulated and three up-regulated ion channels/subunits, and nine upregulated genes
associated with cardiac fibrosis and extracellular matrix components. Genes are listed in
Table 2, including reference to published data reporting similar changes in AF patients.
miRNAs are involved in remodelling of the right atrium
Microarray experiments allowed us to investigate miRNAs expression profiles in RA biopsies.
Different factors were expected to contribute to sample variability due to the heterogeneous
Fig 1. Transcriptome analysis of right atrial biopsies from AF patients compared to controls (SR). A. Principal component analysis (PCA) showing the overall
effect of variances between the transcriptome of samples analysed by RNA-sequencing. B. Volcano plot comparing expression of 44,852 genes in the right atrium of AF
patients in relation to SR. Red dots represent genes with adjusted-p< 0.05 and log2FC> 2 or< -2. C-D. Gene set enrichment analysis of differentially expressed genes.
Top 10 enriched gene ontology terms and pathways with an enrichment p-value< 0.05 after Benjamini-Hochberg correction from up- (C) and down-regulated (D)
genes were plotted. AF–atrial fibrillation; BP–biological processes; CC–cellular component; KEGG–Kyoto Encyclopedia of Genes and Genomes; MF–molecular
function; NS–non-significant; FC—fold change.
https://doi.org/10.1371/journal.pone.0232719.g001
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profile of the study participants (AF duration, gender, age, alcohol consumption). We used
PCA and sample-to-sample distance matrix to evaluate miRNAs expression variations between
samples (S4 Fig in S1 File). We were able to identify a total of 43 miRNAs differentially
expressed between AF and control subjects following a cut-off p< 0.01. Of those, 21 were
down-regulated and 22 were up-regulated in AF patients, as shown in Fig 2. We validated the
microarray experiments by qPCR quantification of eleven miRNAs in three AF and three
Table 2. DEGs associated with AF and potentially involved in electrical and structural remodelling.
AF genes from GWAS and familial studies
Symbol Gene ID log2FC p-value p-adjusted Reference Samples
PHLDA1 ENSG00000139289 2,94 5,79E-19 5,43E-16 [34] -
MYH7 ENSG00000092054 1,97 6,01E-06 3,28E-04 [34] -
NAV2 ENSG00000166833 1,18 2,68E-13 1,23E-10 [34] -
RPL3L ENSG00000140986 1,16 2,48E-15 1,70E-12 EV -
REC114 ENSG00000183324 -3,01 5,71E-24 1,31E-20 [34] -
HCN4 ENSG00000138622 -1,71 5,15E-11 1,50E-08 [34] -
KCNJ5 ENSG00000120457 -1,10 1,85E-12 7,56E-10 [34] -
KCNN2 ENSG00000080709 -1,06 1,86E-10 4,62E-08 [34] -
MYH6 ENSG00000197616 -1,06 3,89E-05 0,0015 EV -
Ion Channel genes
KCNQ4 ENSG00000117013 1,09 0,0021 0,0343 - -
KCNQ3 ENSG00000184156 1,36 1,58E-05 7,49E-04 - -
KCNA4 ENSG00000182255 1,63 2,49E-09 4,50E-07 - -
KCNH7 ENSG00000184611 -2,71 2,29E-07 2,16E-05 - -
KCNQ5 ENSG00000185760 -1,79 1,24E-05 6,13E-04 - -
HCN4 ENSG00000138622 -1,71 5,15E-11 1,50E-08 - -
CACNA2D2 ENSG00000007402 -1,34 3,74E-11 1,13E-08 [36] RA
CACNA1G ENSG00000006283 -1,33 1,71E-07 1,67E-05 [36] RA
KCNK5 ENSG00000164626 -1,32 2,45E-04 0,0066 - -
KCNK17 ENSG00000124780 -1,30 5,34E-04 0,0120 - -
SCN2A ENSG00000136531 -1,29 8,71E-04 0,0174 - -
KCNB1 ENSG00000158445 -1,20 3,96E-04 0,0096 - -
CACNA1D ENSG00000157388 -1,16 3,29E-05 0,0013 [36] RA
KCNJ5 ENSG00000120457 -1,10 1,85E-12 7,56E-10 [36,37] RA, LAA
SCN1A ENSG00000144285 -1,10 0,0029 0,0429 - -
KCNN2 ENSG00000080709 -1,06 1,86E-10 4,62E-08 [37] LAA
SCN3A ENSG00000153253 -1,05 0,0029 0,0423 - -
Extracellular Matrix/Cardiac Fibrosis
NPPB ENSG00000120937 6,61 1,07E-49 8,98E-46 [36,38] RA
COLQ ENSG00000206561 2,90 2,30E-42 1,46E-38 [36–38] RA, LAA
NPPA ENSG00000175206 2,00 4,37E-24 1,10E-20 - -
TNC ENSG00000041982 1,87 0,0014 0,0245 [36,38] RA
COL21A1 ENSG00000124749 1,66 9,52E-12 3,39E-09 - -
COL3A1 ENSG00000168542 1,57 2,57E-06 1,62E-04 - -
COL12A1 ENSG00000111799 1,53 3,01E-07 2,76E-05 [36] RA
COL1A1 ENSG00000108821 1,52 1,11E-04 0,0036 [36,39] RA, RAA
ANGPTL2 ENSG00000136859 1,09 5,47E-11 1,57E-08 [36,37,40] RA, LAA
EV—Ensembl Variation 96; RAA–Right atrial appendage; LAA–left atrial appendage
https://doi.org/10.1371/journal.pone.0232719.t002
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control tissue samples (S5 Fig in S1 File). Altogether, qPCR results were in accordance with
the microarray results. Average expression data from all subjects revealed that amongst the top
20 abundant miRNAs were miR-26a, miR-125b, let-7a/c and miR-23b-3p, thereby confirming
the high expression levels in RA previously shown by others [41].
Amongst the differentially expressed miRNAs identified in this study, ten were reported
previously as abnormally expressed in AF atrial tissues. miR-338-5, miR-10a-5p and miR-
200b-5p were down-regulated in our AF patients with similar results reported in RA free wall
and RA appendage (RAA) tissue samples of AF patients [30,31]. The same was observed with
up-regulated miRNAs, namely miR-30d-5p, miR-216a-5p, miR-106b-3p, miR-130b-3p, miR-
574-5p, miR187-5p and miR-187-3p, which were found to be up-regulated in the same human
AF studies [30,31]. Increasing the p-value cut-off to 0.05, the number of miRNAs dysregulated
in AF increased drastically to a total of 223 (D3 in S1 Dataset), including other commonly AF-
associated miRNAs such as miR-15b, miR-26a-5p, miR-24-3p, miR-208a-5p and miR-193a-5p
[15,30–32,42–44]. Nonetheless, some of the miRNAs most commonly reported dysregulated
in AF, such as miR-1, miR-21 and miR-143, were unchanged in our study [45].
Novel putative miRNA-gene interactions in AF
The 43 dysregulated miRNAs were predicted to bind 166,790 3’-UTR sites of 15,213 unique
target genes. Interaction with genes outside our DEGs list were excluded. miRNAs are
expected to negatively regulate mRNA expression and therefore, expected to have opposite
Fig 2. Micro RNAs expression analysis of right atrial biopsies from AF patients compared to controls (SR). Heatmap
shows the 43 differentially expressed miRNAs in AF hearts. Columns represent samples and rows represent miRNAs. Red
indicates increased expression, blue indicates decreased expression and yellow indicates low variation in relation to the mean
expression.
https://doi.org/10.1371/journal.pone.0232719.g002
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expression results. We analysed the expression correlation in all miRNA-mRNA interaction
pairs using Spearman’s correlation coefficient. Negative correlation ranged -1 to -0.5 were
selected. A total of 905 miRNA-mRNA pairs, including 37 miRNAs and 295 genes, passed the
filtering (D4 in S1 Dataset). Fourteen of the miRNA-mRNA interactions were experimentally
validated according to miRTarBase. We used Cytoscape to visualize the predicted regulatory
networks [29]. Two networks were created, one with up-regulated miRNAs and corresponding
down-regulated target genes (Fig 3) and a second network with down-regulated miRNAs and
corresponding up-regulated target genes (S6 Fig in S1 File).
GO enrichment analysis revealed that our miRNA-gene interactions were enriched in eight
categories (D5 in S1 Dataset). Down-regulated miRNAs were predicted to target genes
Fig 3. miRNA-gene regulatory networks build using Cytoscape. Network includes up-regulated miRNAs and candidate gene targets that were down-regulated in
right atrial biopsies of AF patients compared to control subjects. The network helps to identify miRNAs targeting multiple DEGs and genes targeted by multiple
miRNAs. Triangle nodes represent up-regulated miRNAs with red colour intensity according to FC. Rectangle nodes represent down-regulated genes with blue
colouring according to FC. The darkness of the node to node edges correlates with the expression correlation value between a miRNA and its target gene. The darker the
line, the closer to -1 is the correlation. All miRNA-gene pairs with correlation above -0.5 were excluded from the network. AF–atrial fibrillation; FC–fold-change.
https://doi.org/10.1371/journal.pone.0232719.g003
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enriched for “extracellular space” and “extracellular region” cellular components (Fig 4A). In
up-regulated miRNAs, the most significant enrichments of target down-regulated genes were
related to plasma membrane components, “regulation of ion transmembrane transport” and
“calcium ion binding”. KEGG analysis showed enrichment in the “cAMP signalling pathway”
(Fig 4B).
Amongst the up-regulated miRNAs targeting the most DEGs, we identified miR-4436b-3p,
miR-4728-5p and miR-6124 as putative regulators of 57, 56 and 67 down-regulated genes.
These miRNAs are poorly characterized. Enrichment analysis of the target genes of each
miRNA, revealed that down-regulated genes targeted by miR-6124 are enriched for “calcium
ion binding”. Considering the importance of calcium dysregulation in the triggering of AF
and disease progression of AF [46], it renders miRNA-6124 a potential role in AF. Conversely,
AQP4 and RGS6 were the down-regulated genes predicted to be regulated by the higher num-
ber of overexpressed miRNAs, ten and thirteen respectively.
Lastly, we selected a subset of interactions including exclusively miRNAs that were previ-
ously shown to be dysregulated in AF tissues. The AF related regulatory networks are shown
in Fig 5.
Fig 4. Gene enrichment analysis of micro RNA target genes using GO terms and KEGG. A. Analysis of up-
regulated genes predicted to be targeted by down-regulated miRNAs. B. Analysis of down-regulated genes predicted to
be targeted by up-regulated miRNAs. Enrichment cut-off was p<0.05 after Benjamini-Hochberg correction. BP–
biological processes; CC–cellular component; GO–gene ontology; KEGG—Kyoto Encyclopedia of Genes and
Genomes; MF–molecular function.
https://doi.org/10.1371/journal.pone.0232719.g004
PLOS ONE Investigating gene-microRNA networks in atrial fibrillation patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0232719 May 11, 2020 11 / 21
AF genomic elements co-localize in high-density regions
Genetics factors contributing to AF involve mono- and polygenic mutations and/or dysregulation
of genes and non-coding RNAs, resulting in disrupted protein expression. Additionally, expres-
sion regulators, such as methylation and chromatin modifications, can regulate expression of
entire sets of genes located in proximal genomic regions. To assess a possible chromosomal clus-
tering of our dysregulated miRNAs and DEGs with previously reported AF-associated genetic
variants, we analysed their relative genomic localisation. A total of 1008 genetic components were
integrated in the analysis, including 43 DE miRNAs, 644 DE genes and 321 SNPs. Fig 6A illus-
trates a chromosome plot with the location of all genetic components included in our study.
Chromosomes 1 and 6 show the highest density of genetic elements after normalization, with 107
and 78 elements respectively. Zooming into clusters with five or more genetic elements, we have
identified seven high-density clusters located in chromosomes 2, 6, 11, 14, 15, 16 and 17. For a full
list of clusters, genetics elements and genomic locations, see D6 in S1 Dataset.
An example locus is shown in Fig 6B. The figure represents cluster 580 located in chromo-
some 14 which includes rs422068, rs28631169, MYH6, MYH7, miR-208b and miR-208a.
Another cluster, number 298, is located in the p arm of chromosome 6 and includes the high-
est number of novel genes associated with AF (S7 Fig in S1 File). This cluster is part of the
major histocompatibility complex (MHC) class III gene cluster and contains five up-regulated
Fig 5. AF related miRNA-gene regulatory networks build using Cytoscape. MiRNAs previously associated with AF were selected to create a subset of the regulatory
networks. A. Up-regulated miRNAs and candidate gene targets down-regulated in right atrial biopsies of AF patients compared to control subjects. B. Down-regulated
miRNAs and candidate gene targets up-regulated in AF patients. Triangle nodes represent miRNAs and rectangle nodes represent target genes. Red colour intensity varies
according to expression increase in FC and blue colouring according to decrease in FC. Edges connecting miRNA and genes are coloured according to Spearman
correlation of expression data. The darker the line, the closer to -1 is the correlation. AF–atrial fibrillation; FC–fold-change.
https://doi.org/10.1371/journal.pone.0232719.g005
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genes from our RNA-seq experiments. The MHC III cluster is heterogeneous and poorly char-
acterized. The MHC III region is composed by more than 60 genes encoding signalling mole-
cules involved in inflammatory response and a variety of different cell communication
processes [47].
Furthermore, we analysed the genomic location of dysregulated miRNAs and genes to
assess possible co-expression patterns. 22 of our 42 differentially expressed miRNAs were
located in either intronic or exonic regions. The expression of both miRNA and host genes
was changed in the same direction in ten of the 22 miRNAs. In four of those cases, changes
were significant for both the miRNA and the gene. These findings support previous studies
showing that transcription of intronic and exonic miRNAs is regulated by the same promoter
as their host genes [48,49].
Fig 6. Chromosome enrichment of AF related genetic elements. Enrichment includes AF related SNPs and
differentially expresses genes and miRNAs in right atrium biopsies of AF patients compared to control subjects. A.
Chromosome plots showing the genomic location of all 1008 elements included in the study. B. High-density cluster
identified in the q arm of chromosome 14 including genes MYH6 and MYH7, miR-208a/b and two AF-associated
SNPs. AF–atrial fibrillation; SNPs–single nucleotide polymorphisms; Mbp–million base pairs.
https://doi.org/10.1371/journal.pone.0232719.g006
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Discussion
Transcriptome analysis is a powerful tool to help identify new molecules and pathways of dis-
ease as it allows the simultaneous analysis of coding and non-coding RNAs. To date, few stud-
ies have applied RNA-sequencing to study transcriptome changes in tissue samples from AF
patients [50,51]. In this study, we analyse the expression of genes and miRNAs in RA biopsies
to investigate differences between in MVR patients with and without AF. The strength of our
study is that we assessed miRNA and gene expression from the exact same tissue samples and
pool of extracted RNA, thereby increasing the likelihood of selecting relevant miRNA-mRNA
pairs.
We detected changes of expression in 14 cardiac ion channels that can generate electrical
conductance disturbances. Notably, genes KCNJ5, KCNN2 and HCN4, encoding the inward
rectifier K+-channel subunit Kir3.4 (GIRK4), the small conductance calcium activated potas-
sium channel member 2 KCa2.2 (SK2) and the hyperpolarization activated cyclic nucleotide
gated potassium channel 4 (HCN4), respectively, were down-regulated in AF. These findings
are in line with other transcriptional studies in different atrial samples [36,37]. The three chan-
nels have also been reported in AF GWAS studies. Down-regulation of KCNJ5 is believed to
represent a compensatory mechanism to counteract shortening of the atrial effective refractory
period seen in persistent AF [37]. In the heart, KCNN2 is predominantly expressed in the atria.
Our findings of reduced KCNN2 expression in AF are consistent with Skibsbye et al. who
reported KCNN2 down-regulation and reduced functional importance of the channel in
chronic AF [52].
Genes associated with increased cardiac fibrosis and extracellular matrix were upregulated
in AF patients. This is an indicator of structural remodelling in hearts of AF patients mediated
by interstitial fibrosis due to accumulation of collagen fibres and fibroblasts in the extracellular
matrix. The fibrotic processes can be induced via activation of the TGF-ß1/Smad3 signalling
pathway with increase COL1A1 and COL3A1 expression [53]. Unfortunately, we were unable
to investigate interstitial fibrosis in our AF patients, due to limited tissue availability. Lastly, we
found NPPB to be up-regulated by almost 7-fold in our AF patients. NPPB encodes the natri-
uretic peptide B protein secreted by cardiac myocytes. We hypothesize that its up-regulation
might be a response to cardiac fibrosis due to its anti-fibrotic function [54]. Overall, the
changes in genes expression described here are in line with the electrical, contractile, and
structural remodelling characteristic of AF hearts. We hypothesize that the more severe
remodelling of the heart in certain MVR patients can be the key factor to create the trigger and
subtract for development and maintenance of AF. The contribution of structural remodelling
to AF susceptibility was also described by in two previous studies [55,56], both showing that
more severe fibrosis in RA and LA was associated with increased susceptibility to develop AF
in patients with concomitant heart disease and after cardiac surgery.
As negative regulator of gene expression, miRNAs bind to the 3’-UTR of target genes to
inhibit protein production, by preventing translation by ribosomes and promoting mRNA
degradation [11]. Importantly, a gene simultaneously targeted by multiple miRNAs is more
likely to be regulated by miRNAs. Likewise, overexpressed miRNAs that target multiple genes
are more likely to have an important role in a specific tissue [57]. Hence, it is important to
study the collective action of miRNAs in disease. In the present study, differentially expressed
miRNAs include ten miRNAs previously reported as changed in AF tissues, but with little
known about their functional role. We built an AF related regulatory network including 905
miRNA-target gene pairs that can play a role in the development of AF in MVR patients.
Aquaporin 4 (AQP4) and regulator of G-protein signalling 6 (RGS6) were the down-regu-
lated genes predicted to be targeted by the highest number of DE miRNAs. AQP4 contributes
PLOS ONE Investigating gene-microRNA networks in atrial fibrillation patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0232719 May 11, 2020 14 / 21
to maintenance of water and electrolyte balance in aging hearts and its decreased expression
might compromise homeostasis in cardiac cells [58]. RGS6 is involved in modulation of para-
sympathetic regulation of heart rate. Down-regulation of RGS6 can contribute to electrical
remodelling and shortening of the action potential by increasing the activation time of the G
protein-coupled inwardly rectifying K+ Kir3.1/3.4 (GIRK) channel, resulting in a large K
+ cur-
rent and membrane hyperpolarization [59,60].
MiR-338-5p targeted 14 of our DEGs, including IGFBP2, LBH and NPPA. IGFBP2 and
LBH have both been reported as up-regulated in three different AF studies and they are
increased by 8 and 3 FC in our RA samples, respectively [36–38,40]. Mutations in NPPA have
been associated with familial AF [61]. NPPA encodes the natriuretic peptide A protein, a circu-
latory hormone released from atrial cardiomyocytes upon stretching. The NPPA protein plays
a role in cardiac electrophysiological function, where it shortens the atrial effective refractory
period and conduction velocity in human hearts by inhibiting sympathetic and parasympa-
thetic activity or through direct regulation of cardiac ion channels [62–64]. MiR-338-5p was
also reported as down-regulated in RAA of AF patients with mitral stenosis [30]. This miRNA
has also been implicated in tumor progression and reported to alleviate lung fibrosis [65,66].
MiR-130b-3p was upregulated in RA samples in line with a previous study [31]. MiR-130b-
3p is predicted to bind 15 of our down-regulated genes, amongst those there are CACNA2D2
and SLC7A11 which have been reported as down-regulated in AF transcriptomics studies
[36,38,67]. CACNA2D2 is a subunit of the voltage-gated calcium channel that modulates the
calcium signalling response in cardiomyocytes and induces arrhythmia when down-regulated
[68].
Genomic co-localization analysis helped mark regions of interest in the long list of DE
genes and miRNAs. A high-density cluster in chromosome 14q11.2 marked a genetic locus
that includes genes MYH6, MYH7, miR-208a, miR-208b and SNPs rs422068 and rs28631169
within 20 kbp of distance. We find miR-208a down-regulated in AF patients by increasing the
array analysis p threshold to 0.05. The same was reported in RAA from AF patients and atria
of ventricular tachypaced dogs [30,32,69]. MiR-208a-3p was described by Li et al. to regulate
the expression of connexin 40 in the heart, resulting in electrical impulse propagation defects
between adjacent cardiac myocytes [70]. Furthermore, miR-208a-3p is believed to generate
protective effects in myocardial infarction and it could become a potential treatment for struc-
tural remodelling in AF [71]. Genetic deletion of miR-208a in mouse hearts interferes with
cardiac conduction, with lack of P waves in ECG recordings and an AF like phenotype [72].
MiR-208a is encoded by an intron of the MYH6, which is also down-regulated in our samples,
therefore suggesting that miR-208a is co-expressed with its host gene. MYH6 is an important
protein in cardiac muscle fibre composition, involved in muscle contraction mechanisms.
Both miR-208a and MYH6 are expressed predominantly in the atrial chambers. MYH7 and
miR-208b are up-regulated in our RNA-seq studies by 4 and 3.5 FC, suggesting once again co-
expression. MYH7 is mainly expressed in the ventricular chambers and is part of sarcomere
formation, therefore involved in cardiac contraction mechanisms. Several MYH7 mutations
have been reported in cardiac muscle disorders, including AF [73]. MiR-208b was reported
up-regulated in isolated myocytes from chronic AF patients and is involved in calcium homeo-
stasis and contractile remodelling [74]. In conclusion, our study emphasizes the significance of
chr14q11.2 as a AF susceptibility locus.
Study limitations
The study cohort size is modest and challenges the assessment of the effect of confounding fac-
tors in the results. Furthermore, it is important to mention that different studies investigating
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miRNA and gene expression in atrial samples from AF patients overlap poorly [45]. These
inconsistencies might reflect 1) heterogeneity between tissue samples (location and collection
method), 2) AF type and duration, 3) variation in patient cohorts (comorbidities, life-style,
age, medication), and 4) the experimental technique selected to study transcript changes. In
fact, our RNA-seq results overlap best with gene expression profiling studies from Jiang et al.
using similar tissue samples and experiments [38]. A continuous effort from experts to study
larger cohorts and collect similar datasets will allow a combined analysis of multiple samples
from AF patients and help on accurate selection of target genes and regulatory networks
involving miRNAs.
The in silico miRNA-target gene predictions provide qualified results which are generally
accepted by research. However, these interactions require further validation and functional
studies to clarify the pathophysiological role of such interactions, such as luciferase assays and
in vitro miRNA transfections.
Lastly, the functional role of each DEG in AF is difficult to estimate since many genes are
not yet characterized and we miss information on cell type specificity. For instance, we see
down-regulation of KCNQ5 in our AF samples, a gene known for being mainly expressed in
neuronal, skeletal and smooth muscle cells and therefore, not expected to interfere with car-
diac electrical conductance [75]. Single-cell gene expression studies would allow us to detect
the cell population creating the change, giving a better idea of the mechanism in which each
DEG is involved.
Conclusions
By combining miRNA and gene expression data from RA of MVR patients with AF, we were
able to create a novel miRNA-mRNA regulatory network, providing new insights into the
mechanism predisposing certain MVR patients to develop and maintain AF. Down-regulation
of ion channel genes and up-regulation of extracellular matrix genes summarize the major
changes creating a subtract for AF. Lastly, we identified a high-density AF loci in chromosome
14q11.2.
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